Polymer Capital Management HK LTD Makes New $317,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Polymer Capital Management HK LTD purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,003 shares of the medical research company's stock, valued at approximately $317,000.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its position in Natera by 7.7% in the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after acquiring an additional 879,463 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares during the last quarter. Geode Capital Management LLC increased its position in Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after purchasing an additional 142,201 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in Natera by 40.0% in the 4th quarter. Franklin Resources Inc. now owns 1,538,875 shares of the medical research company's stock valued at $243,604,000 after purchasing an additional 439,540 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Remove Ads

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the business's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John Fesko sold 663 shares of the firm's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock valued at $51,603,664 in the last three months. Corporate insiders own 7.60% of the company's stock.

Natera Trading Up 3.3 %

Shares of NTRA stock traded up $4.76 during trading hours on Friday, hitting $148.04. 1,364,917 shares of the company were exchanged, compared to its average volume of 1,394,665. The company has a 50 day simple moving average of $152.66 and a two-hundred day simple moving average of $152.05. The firm has a market cap of $20.01 billion, a P/E ratio of -84.11 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Guggenheim upped their price target on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Sanford C. Bernstein upped their target price on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, January 10th. The Goldman Sachs Group lifted their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. BTIG Research reiterated a "buy" rating on shares of Natera in a report on Friday, February 28th. Finally, Piper Sandler boosted their target price on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $175.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.